Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Forecasted Market Size of the Frasier Syndrome Market by 2029?
The frasier syndrome market size has grown strongly in recent years. It will grow from $1.48 billion in 2024 to $1.58 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing awareness of rare genetic disorders, rising prevalence of pediatric kidney diseases, growing clinical focus on intersex conditions, increasing patient referrals to genetic counselors, and rising use of hormone therapy in congenital cases.
The frasier syndrome market size is expected to see strong growth in the next few years. It will grow to " $2.07 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing demand for personalized medicine, increasing early diagnosis in newborn screening programs, rising focus on gender-affirming healthcare, increasing accessibility to rare disease support services, and growing prevalence of congenital nephrotic syndromes. Major trends in the forecast period include technological advancements in genetic testing, innovation in hormone replacement therapies, development of precision nephrology tools, investment in rare disease research and development, and advancement in pediatric urology care solutions technology.
Get your free report sample today:
What Are the Major Drivers Propelling the Growth of the Frasier Syndrome Market?
The rising prevalence of kidney-related diseases is expected to propel the growth of the Frasier syndrome market going forward. Kidney-related diseases are a group of medical conditions that affect the structure or function of the kidneys, limiting their capacity to filter waste, balance fluids, and control essential physiological functions. The increase in kidney-related diseases is primarily due to rising rates of diabetes and high blood sugar levels that damage kidney blood vessels, reducing their ability to filter waste effectively. Frasier syndrome enhances the understanding of kidney-related diseases by highlighting the role of genetic mutations in kidney function. It provides insights into how genetic factors can contribute to nephropathy, improving diagnosis and management of kidney disorders. For instance, in December 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease (CKD) accounted for around 22,000 deaths in 2022. Additionally, the death rate rose from 56.7 per 100,000 in 2021 to 60.3 per 100,000 in 2022. Therefore, the rising prevalence of kidney-related diseases is driving the growth of the frasier syndrome market.
How Is the Frasier Syndrome Market Structured Across Its Key Segment Categories?
The frasier syndromemarket covered in this report is segmented –
1) By Treatment Type: Surgical Intervention; Hormone Therapy; Supportive Care; Genetic Counseling
2) By Diagnosis Method: Genetic Testing; Clinical Evaluation; Imaging Techniques; Biochemical Testing
3) By Symptoms: Hypospadias; Nephropathy; Hearing Loss; Dental Anomalies
4) By End Users: Hospitals; Diagnostic Centers; Research Institutes; Other End Users
Subsegments:
1) By Surgical Intervention: Nephrectomy; Renal Transplantation; Testicular Biopsy
2) By Hormone Therapy: Testosterone Replacement Therapy; Estrogen Therapy; Growth Hormone Therapy
3) By Supportive Care: Blood Pressure Management; Renal Replacement Therapy (Dialysis); Pain Management
4) By Genetic Counseling: Preconception Counseling; Post-Diagnosis Counseling; Family Planning Guidance
Which Companies Are Recognized as Major Innovators in the Frasier Syndrome Market?
Major companies operating in the frasier syndrome market are Pfizer Inc, Bayer AG, Novo Nordisk, Merck KGaA, Quest Diagnostics Incorporated, Genentech Inc, Illumina Inc., Revvity Inc., Exact Sciences Corporation, Natera Inc., PTC Therapeutics, Myriad Genetics Inc., Fulgent Genetics Inc., Guardant Health Inc., Invitae Corporation, GeneDx LLC, Travere Therapeutics, Centogene N.V., Prevention Genetics, Medicover Hospitals
Get the detailed frasier syndrome market report today
Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
North America was the largest region in the frasier syndrome market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the frasier syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment